When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CRTPF - Cardiol Therapeutics on go with study of cannabidiol for COVID-19
Cardiol Therapeutics
The FDA has signed off on a U.S. Phase 2/3 clinical trial evaluating Cardiol Therapeutics' (CRTPF) CardioRx, an extra-strength formulation of cannabidiol, in 422 hospitalized COVID-19 patients with prior histories of of risk factors cardiovascular disease ((CVD)).The study's objective is to assess the safety, tolerability and efficacy of CardioRx in preventing CV complications in COVID-19 patients within 24 hours of diagnosis.